Aberrant phosphorylation of MEF2C is dispensable for hematopoiesis, and induces chemotherapy resistance and susceptibility to MARK kinase inhibition therapy in acute myeloid leukemia Meeting Abstract
| Authors: | Brown, F. C.; Still, E.; Cifani, P.; Reed, C.; Ficarro, S.; He, J.; Koche, R.; Bhola, P.; Romanienko, P.; Mark, W.; Krivtsov, A. V.; Letai, A.; Gray, N.; Marto, J.; Armstrong, S. A.; Kentsis, A. |
| Abstract Title: | Aberrant phosphorylation of MEF2C is dispensable for hematopoiesis, and induces chemotherapy resistance and susceptibility to MARK kinase inhibition therapy in acute myeloid leukemia |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446802025 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.436.436 |
| Notes: | Meeting Abstract: 436 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
